Drugs / MI078
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06982651 | Sep 2023 → Mar 2024 | postpartum depression | Nanjing Minova Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06963580 | Sep 2024 → Aug 2025 | postpartum depression | Nanjing Minova Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MI078 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06982651 ↗ |
| Route | Oral | “Administration and Dosage: Oral.” NCT06982651 ↗ |